Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors

Published:2020-08 Issue:8 Volume:10 Page:1476-1491
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Liu Zhenzhen,Zhao Taoqian,Li Zhonghua,Sun Kai,Fu Yundong,Cheng Ting,Guo Jimin,Yu Bin,Shi Xiaojing,Liu Hongmin

Funder

National Key Research Program of Proteins

National Natural Science Foundation of China

Scientific Program of Henan Province

China Postdoctoral Science Foundation

Henan Scientific Innovation Talent Team

Department for Education

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference28 articles.

1. Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics;Lill;Trends Pharmacol Sci,2014

2. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes;Reyes-Turcu;Annu Rev Biochem,2009

3. Proteasome deubiquitinases as novel targets for cancer therapy;D'Arcy;Int J Biochem Cell Biol,2012

4. Ubiquitin signaling in immune responses;Hu;Cell Res,2016

5. Breaking the chains: structure and function of the deubiquitinases;Komander;Nature,2009

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the development of P2Y ₁₄ R inhibitors: a patent and literature review (2018-present);Expert Opinion on Therapeutic Patents;2024-06-19

2. Structural basis for the bi-specificity of USP25 and USP28 inhibitors;EMBO Reports;2024-05-30

3. Strategies that regulate LSD1 for novel therapeutics;Acta Pharmaceutica Sinica B;2024-04

4. Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer;Biomedicine & Pharmacotherapy;2024-04

5. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer;Biomedicine & Pharmacotherapy;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3